secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001493152-24-007115
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA agrees on Phase 3 trial design for Matinas' MAT2203 in invasive aspergillosis
--------------------------------------------------------------------------------

- FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis; primary endpoint all-cause mortality at day 42.
- Trial will enroll ~216 adults with limited treatment options; 2:1 randomization to oral MAT2203 vs continued AmBisome + SOC.
- Key secondary endpoint: superiority of MAT2203 over AmBisome for treatment-related toxicities leading to treatment changes.
- Enrollment expected to begin H2 2024, complete in ~24 months at ~65 sites across US, Europe, South America, Middle East, Asia Pacific.
- CEO says FDA alignment provides certainty to advance partnership discussions; product not yet approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224007115/0001493152-24-007115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224007115/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer